Could a pill prevent relapse after transplant for blood cancer?
NCT ID NCT04980404
First seen Apr 04, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This early-phase study tests whether the oral drug Inqovi (decitabine/cedazuridine) can reduce the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will take Inqovi as maintenance therapy. The main goal is to find the safest and most effective dose schedule.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.